Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Genprex Inc (NQ: GNPX )

0.2490 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 27, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.2490
Bid (Size) 0.2490 (1)
Ask (Size) 0.2900 (30)
Prev. Close 0.2490
Today's Range 0.2490 - 0.2490
52wk Range 0.1903 - 1.940
Shares Outstanding 59,409,822
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Genprex Inc. (NASDAQ: GNPX) Granted Orphan Drug Designation in Small Cell Lung Cancer by FDA, Presented Data at Two October Events Focused on Lung Cancer
Via Investor Brand Network
Exposures Product Safety
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga

Performance

YTD
-84.34%
-84.34%
1 Month
+22.06%
+22.06%
3 Month
-46.74%
-46.74%
6 Month
-69.00%
-69.00%
1 Year
-81.14%
-81.14%

More News

Read More
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present at BIO-Europe 2023
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Schedules, Hosts Virtual Key Opinion Leader Event
Via Investor Brand Network
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Unveil Encouraging Data on REQORSA(R) for Lung Cancer Treatment at 2023 AACR-NIH-EORTC Conference
Via Investor Brand Network
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Genprex Inc. (NASDAQ: GNPX) Receives Orphan Drug Designation for Immunogene Therapy for Treatment of SCLC
From Genprex, Inc.
Via GlobeNewswire
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Building Protection and Powerful IP Portfolio for Its Diabetes Gene Therapy Program
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation
Via Investor Brand Network
Exposures Product Safety
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation
Via FinancialNewsMedia
Exposures Product Safety
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Looks Forward to Acclaim-3 Trial on Heels of Receipt of FDA FTD and ODD Designations
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present at Upcoming H.C. Wainwright Conference
Via Investor Brand Network
Exposures Product Safety
Genprex Inc. (NASDAQ: GNPX) Obtains New License for Novel Diabetes Gene Therapy Pipeline
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Secures Patent Protection in ‘Some of the Most Important Markets in the World’
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property Product Safety
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Genprex Inc. (NASDAQ: GNPX) Celebrates Receipt of Orphan Drug Designation, Third Fast Track Designation Amid Preparations for Planned Acclaim-3 Clinical Trial
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Appoints Regulatory Expert as It Drives Important Clinical Programs Forward
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Granted FDA Orphan Drug Designation for REQORSA(R) for Patients with SCLC
Via Investor Brand Network
Exposures Product Safety
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
BioMedNewsBreaks – Genprex Inc.’s (NASDAQ: GNPX) Third Fast Track Designation Validates REQORSA(R)’s Potential
Via Investor Brand Network
Exposures Product Safety
Genprex Inc. (NASDAQ: GNPX) Secures Exclusivity for REQORSA(R)-Keytruda(R) Drug Combination in China with Chinese Patent
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Closes on $7.5M Registered Direct Offering
Via Investor Brand Network
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces $7.5M Registered Direct Offering
Via Investor Brand Network
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.